Concurrence of Rheumatoid Arthritis and Ankylosing Spondylitis: Analysis of Seven Cases and Literature Review

Bryan-Josué Flores-Robles, Eztizen Labrador-Sánchez, Estíbaliz Andrés-Trasahedo, Valvanera Pinillos-Aranzay, María-Yasmina Joven-Zapata, Laura Torrecilla Lerena, Osman-Alberto Salazar-Asencio, and Juan-Antonio López-Martín

1San Pedro Hospital, Logroño, La Rioja, Spain Rheumatology Department
2San Pedro Hospital, Logroño, La Rioja, Spain Nursing Department
3Son Espases University Hospital, Palma, Islas Baleares, Spain Neurosurgery Department, Spain

Correspondence should be addressed to Bryan-Josué Flores-Robles; aldolasa@hotmail.com

Received 11 August 2021; Accepted 10 May 2022; Published 28 May 2022

Copyright © 2022 Bryan-Josué Flores-Robles et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. The association of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in a single patient is a rarely described phenomenon. AS and RA are conditions that can have a high impact on the morbidity and mortality of patients. Methods. We described the clinical, epidemiological, analytical, and radiological characteristics of 81 patients with concomitant diagnosis of rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Of these patients, seven were diagnosed at our hospital. A literature review was carried out using Medline, Embase, Scopus, and virtual hospital libraries, including the period from January 1950 to April 2020. Results. Regarding the results, 71% of the patients were men, with a mean age of 53 years (±14.83). RA was the first disease diagnosed in 52% of the cases. Approximately 53% of the patients had rheumatoid nodules, and 83% reported inflammatory lumbar pain during their evaluation. Erosions were observed on radiographs of the hands and/or feet in 85% of the cases, and almost all the patients (80/81) had sacroiliitis on imaging studies. Approximately 92% of the cases were rheumatoid factor (RF) positive and 90% HLA B-27 positive. Conclusions. The coexistence of RA and AS is highly uncommon. With the data obtained in this review, it seems that there exist erosive radiological patterns, positivity for RF, involvement of the axial skeleton, and rheumatoid nodules at a higher frequency than those patients with a single diagnosis of the two entities. More data are needed to corroborate this association.

1. Introduction

The association of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in a single patient is a rarely described phenomenon [1]. AS and RA are conditions that can have a high impact on both the quality of life and the morbidity and mortality of patients [2–4]. Initially, both diseases can manifest similar clinical symptoms such as morning stiffness, pain of an inflammatory nature, and arthritis [2–4]. For this reason, in a patient with RA and axial affectations or a patient with AS and symmetric peripheral joint affectations, it is advisable to extend the study to determine if there is a concurrence of these two diseases [4]. Until the 1970s, both processes were not fully distinguishable from one another; however, the discovery of HLA B-27 and its association with AS marked a turning point.

RA is a disease that predominantly affects women, with a prevalence of 0.5–1% and a typical clinical presentation consisting of symmetric polyarthritis and small joints, with the axial skeleton usually remaining unchanged [1]. In contrast, AS is a disease that predominantly affects male, with a prevalence of 0.1–0.2%, whose main clinical manifestation is inflammatory axial pain and which can manifest with peripheral arthritis in up to 30% of cases (mainly asymmetric and in the lower limbs) [3]. The exact incidence of the coexistence of both diseases in the same person is
unknown. However, according to published data, it is estimated that it oscillates between 1 in 500,000 and 1 in 2,000,000 [3, 4]. Up until 1995, approximately 44 cases [3, 4] had been recorded, with a number of discrepancies existing in the literature review; however, the research here presented describes 81 cases (including 7 from our own center).

2. Methods

The RA database of our center (658 patients) was reviewed beginning with the first diagnosis of the association between RA and AS. A total of 18 HLA B-27+ patients were selected. Of these, 7 met AS classification criteria [5] and, as a result, were evaluated by the same physician in person on a single occasion, after having signed the informed consent form.

Subsequently, a literature review was carried out (including the period from January 1950 to April 2020) using the following terms: rheumatoid arthritis, ankylosing spondylitis, coexistence and/or concomitance, and/or association and/or concurrence. A total of 42 articles were obtained, of which 35 were selected (in 7 of them, this association was not adequately described or they were non-specific population studies). The search platforms used were PubMed, Medline, Embase, Scopus, and virtual hospital libraries. All papers were considered regardless of language.

2.1. Statistical Analysis. A descriptive analysis of the categorical variables was carried out using absolute and relative frequencies, and in the case of numerical variables, analysis was done through the mean and standard deviation or median and the 25th and 75th percentiles, according to compliance with the assumption of normality. Bivariate analysis was carried out using Student’s t-test or the Mann–Whitney U test to contrast numerical variables, and the chi-squared test or Fisher’s exact test was used to contrast the hypotheses of categorical variables, as appropriate. The significance level was set at 0.05, and all tests were two-tailed. The statistical package SPSS version 24 was used.

3. Results

81 patients were included in the study here presented. Of these, 74 were those detected in the literature review [6–40] and 7 from our center. Of the total number of cases, 58 were men (71%), with a mean age of 53 years (±14.83), and a mean age of the onset of the disease was 34 years (±14.87). RA was the first disease diagnosed in 52% of cases. The mean duration of the disease (RA or AS) up to the time of diagnosis was 18 years (±13.16). The first symptom suffered was lower back pain in 48% (38/76), followed by arthritis in 46% (35/76) of the cases. 52% of the patients (38/73) had rheumatoid nodules, and 83% had suffered from inflammatory lower back pain at some point during their evaluation. Uveitis was detected in 13% of the patients (11/81). Extra-articular symptoms manifested in 18% (15/81), including 4 cases of Felty syndrome, most of which having manifested when conventional immunosuppressive therapy and/or biological therapy had not been available (Table 1).

Regarding imaging studies, spinal syndesmophytes were present in 73% of cases. 85% (65/76) presented erosions of the hands and/or feet in their radiographs. Radiological sacroiliitis was observed in almost all patients (80/81).

Regarding laboratory findings, RF was positive in 92% and, in 16 of 18 cases in which anti-CCP antibodies were quantified, these turned out to be positive. Finally, almost 90% of the patients were HLA B-27 positive (Table 2). No difference was of statistical significance because the sample size was small.

The treatment used was only carried out in 47 of the 81 cases. Of these, 83% had received a course of corticosteroids at one point in time. Nonsteroidal anti-inflammatory drugs were used in 59% of the cases. 25% of the patients were administered gold salts (with the last case being registered in 1995). Both hydroxychloroquine and sulfasalazine were used in 19% of the cases. With regard to methotrexate, there is evidence that the first patient was treated in 1993, with a total of 15 cases being treated. Anti-TNF-alpha therapy was used in 5 cases, in 2 of them infliximab and in another 2 adalimumab. Other less frequently used therapies were leflunomide, rituximab, D-penicillamine, azathioprine, and synoviotherapy (Table 3).

4. Discussion

In 1958, Wilkinson and Bywaters published a descriptive study of 222 patients with spondylitis that was carried out from 1940 to 1955 [36]. In one of the cases, a 55-year-old male patient was described as having symmetric arthritis, small joints, and subcutaneous nodules and was RF+. Later, in the evolution of his disease, he manifested typical AS symptoms, which at that time were diagnosed as “rheumatoid spondylitis.” This appears to be the first well-documented case of the coexistence of RA and AS. Based on this description, approximately 81 cases have been published (including 7 cases from our center). It is a highly infrequent association in a single patient that is a diagnostic challenge due to the similarities that exist between both diseases, mainly from a clinical perspective [4]. It is likely that the coexistence of both processes in a single patient is underestimated, as shown in a study in 2017, where in 286,601 patients with RA, the association with other autoimmune processes was evaluated, observing that 1.16% of patients also manifested AS [1].

AS and RA are considered to be two independent diseases due to their clinical, genetic, pathogenic, and analytical differences [3]. That is why the probability of the coexistence of these two entities in the same patient is low. However, some authors suggest that the initial cause that acts as a trigger in both diseases may be the same [28].

There are some different characteristics between each of these pathologies. For example, AS mainly affects the axial skeleton, and almost all patients report lower back pain with inflammatory characteristics, also associated with enthesitis. These signs and symptoms are usually asymmetric, rarely involving the upper limbs [28]. Regarding patients with RA, joint involvement is fundamentally symmetrical,
| Author                      | No. | Sex | Age (years) | 1st symptom | Onset (years) | 1st disease | Duration (years) | Nodules | RF | Ac. CCP | HLA B-27 | Lumbar pain | SI | Sind | Eros | Uveitis Extra-art involv |
|-----------------------------|-----|-----|-------------|--------------|---------------|-------------|------------------|---------|----|---------|----------|-------------|----|------|------|------------------------|
| Wilkinson and Bywaters      | 1 M | 55  | Arthritis   | 22           | RA            | 33          | +                | +       | +  | NA      | NA       | +           | +  | NS   | +    | +                     |
| Martel and Duff             | 2 M | 47  | Arthritis   | 18           | RA            | 29          | 0                | +       | +  | NA      | NA       | +           | 0  | +    | +    | 0                     |
|                            | 3 F | 32  | Arthritis   | 30           | RA            | 2           | +                | +       | +  | NA      | NA       | +           | +  | +    | +    | 0                     |
|                            | 4 F | 27  | Arthritis   | 15           | RA            | 12          | +                | +       | +  | NA      | NA       | 0           | +  | +    | +    | 0                     |
|                            | 5 F | 42  | Arthritis   | 24           | RA            | 18          | +                | +       | +  | NA      | NA       | 0           | +  | +    | NS   | +                     |
|                            | 6 M | 52  | Arthritis   | 21           | RA            | 31          | +                | +       | +  | NA      | NA       | 0           | +  | +    | +    | 0                     |
|                            | 7 M | 37  | Arthritis   | 29           | RA            | 8           | 0                | 0       | NA | NA      | +         | +           | NS | +    | +    | +                     |
|                            | 8 M | 54  | Arthritis   | 43           | RA            | 9           | +                | +       | NA | NA      | 0         | 0           | NS | +    | +    | 0                     |
|                            | 9 M | 26  | Arthritis   | 14           | RA            | 12          | +                | NA      | 0  | NA      | NA       | +           | +  | NS   | NS  | 0                     |
| London and Bland            | 10 M| 73  | Uveitis     | 22           | AE            | 51          | +                | +       | NA | NA      | +         | +           | +  | +    | NS   | +                     |
| Rosenthal et al. [8]        | 11 M| 80  | L. pain     | 25           | AE            | 55          | +                | +       | NA | NA      | +         | +           | +  | +    | +    | 0                     |
| Husskisson et al. [37]      | 12 F| 45  | Arthritis   | 36           | RA            | 9           | +                | +       | NA | NA      | +         | +           | NS | +    | +    | 0                     |
| Valkenburgh et al. [9]      | 13 M| 59  | L. pain     | 34           | AE            | 25          | +                | +       | NA | +       | +         | +           | +  | +    | +    | 0                     |
| Luthrah et al. [10]         | 14 M| 65  | L. pain     | 48           | AE            | 17          | +                | +       | NA | +       | +         | +           | +  | +    | +    | 0                     |
|                             | 15 M| 40  | L. pain     | 18           | AE            | 22          | 0                | 0       | NA | +       | +         | 0           | +  | 0    | +    | 0                     |
|                             | 16 F| 46  | L. pain     | 27           | AE            | 19          | 0                | +       | NA | +       | +         | +           | +  | 0    | +    | 0                     |
|                             | 17 M| 51  | L. pain     | 25           | AE            | 26          | +                | +       | NA | +       | +         | +           | +  | 0    | +    | 0                     |
|                             | 18 M| 50  | L. pain     | 42           | AE            | 8           | 0                | 0       | NA | +       | +         | +           | +  | +    | +    | 0                     |
|                             | 19 M| 53  | L. pain     | 41           | AE            | 12          | +                | +       | NA | +       | +         | +           | +  | +    | +    | 0                     |
|                             | 20 M| 17  | L. pain     | 15           | AE            | 2           | 0                | +       | NA | +       | +         | 0           | +  | +    | +    | 0                     |
|                             | 21 M| 28  | L. pain     | 15           | AE            | 13          | 0                | 0       | NA | +       | +         | 0           | +  | +    | +    | 0                     |
| Fallet et al. [35]          | 22 M| 64  | L. pain     | 30           | AE            | 34          | +                | +       | NA | +       | +         | +           | +  | +    | +    | 0                     |
|                             | 23 M| 68  | Arthritis   | 29           | RA            | 39          | 0                | +       | NA | +       | NS        | +           | +  | +    | +    | 0                     |
|                             | 24 F| 68  | Arthritis   | 65           | RA            | 3           | +                | +       | NA | +       | 0         | +           | NS | 0    | 0    | 0                     |
|                             | 25 M| 54  | Arthritis   | 40           | RA            | 14          | +                | +       | NA | +       | +         | +           | +  | +    | +    | 0                     |
|                             | 26 M| 67  | Arthritis   | 57           | RA            | 10          | 0                | +       | NA | 0       | +         | +           | +  | +    | +    | 0                     |
|                             | 27 F| 75  | Arthritis   | 63           | RA            | 12          | 0                | +       | NA | +       | +         | +           | +  | +    | +    | 0                     |
|                             | 28 F| 58  | Uveitis     | 42           | RA            | 16          | 0                | +       | NA | +       | 0         | +           | NS | +    | +    | 0                     |
|                             | 29 M| 68  | L. pain     | 29           | AE            | 39          | 0                | +       | NA | +       | +         | +           | NS | +    | +    | 0                     |
|                             | 30 M| 44  | Myalgias    | 36           | AE            | 8           | +                | +       | NA | +       | +         | +           | NS | +    | +    | 0                     |
| Good et al. [12]            | 31 M| NS  | L. pain     | 29           | AE            | NS          | 0                | +       | NA | +       | +         | +           | +  | +    | +    | 0                     |
|                             | 32 M| NS  | L. pain     | 20           | AE            | NS          | 0                | +       | NA | +       | +         | +           | +  | +    | +    | 0                     |
|                             | 33 M| NS  | L. pain     | 34           | AE            | NS          | 0                | +       | NA | +       | +         | +           | +  | +    | +    | 0                     |
| Clayman and Reinertsen      | 34 M| 48  | L. pain     | 21           | AE            | 27          | +                | +       | NA | +       | +         | +           | +  | +    | +    | 0                     |
| Espinoza et al. [14]        | 35 M| 53  | L. pain     | 47           | AE            | 6           | +                | +       | NA | +       | +         | +           | NS | +    | 0    | 0                     |
| Major et al. [15]           | 36 M| 64  | L. pain     | 28           | AE            | 36          | +                | +       | NA | +       | +         | +           | +  | +    | +    | 0                     |
| Lemmer and Irby             | 37 M| 61  | L. pain     | 61           | AE            | NS          | 0                | +       | NA | +       | +         | +           | +  | +    | +    | 0                     |
| Alexander et al. [17]       | 38 M| 51  | L. pain     | 26           | AE            | 25          | +                | +       | NA | +       | +         | +           | +  | +    | +    | 0                     |
|                             | 39 M| 55  | Arthritis   | 32           | RA            | 23          | +                | +       | NA | +       | +         | +           | NS | +    | 0    | 0                     |
|                             | 40 M| 61  | Arthritis   | 54           | RA            | 7           | +                | +       | NA | +       | +         | 0           | +  | +    | +    | 0                     |
|                             | 41 M| NS  | NS          | NS           | NS          | NS          | NS               | +       | NA | 0       | NS        | NS          | 0  | 0    | 0    | 0                     |
|                             | 42 M| NS  | NS          | NS           | NS          | NS          | NS               | +       | NA | 0       | NS        | NS          | 0  | 0    | 0    | 0                     |
|                             | 43 M| NS  | NS          | NS           | NS          | NS          | NS               | +       | NA | +       | NS        | NS          | 0  | 0    | 0    | 0                     |
| Author | No. | Sex | Age (years) | 1st symptom | Onset (years) | 1st disease | Duration (years) | Nodules | RF | Ac. CCP | HLA B-27 | Lumbar pain | SI | Sind | Eros | Uveitis | Extra-art involv |
|--------|-----|-----|-------------|-------------|--------------|-------------|----------------|----------|----|---------|----------|-------------|----|------|------|--------|----------------|
| Lavery et al. [18] | 44 | M | 60 | L. pain | 18 | AE | 42 | + | + | NA | + | + | NS | + | + |
| Alarcón Segovia and Martínez-Cordero | 45 | M | 70 | L. pain | NS | NS | NS | + | + | NA | + | + | + | + | 0 | 0 |
| Serrano et al. [20] | 46 | M | 35 | NS | 22 | RA | 13 | NS | + | NA | + | + | NS | NS | 0 | + |
| Fallet et al. [21] | 47 | M | 52 | Arthritis | 25 | RA | 27 | 0 | + | NA | + | + | + | + | 0 | 0 |
| | 48 | M | 60 | L. pain | 48 | AE | 12 | + | + | NA | + | + | + | 0 | 0 | 0 |
| | 49 | M | 61 | Arthritis | 40 | NS | 11 | 0 | + | NA | + | + | 0 | + | 0 | 0 |
| | 50 | M | 56 | L. pain | 22 | AE | 34 | 0 | + | NA | + | + | + | + | 0 | 0 |
| | 51 | M | 66 | Arthritis | 61 | RA | 5 | + | + | NA | + | + | 0 | + | 0 | 0 |
| | 52 | M | 71 | L. pain | 21 | AE | 50 | + | + | NA | + | + | + | + | 0 | 0 |
| | 53 | M | 49 | Arthritis | 35 | RA | 14 | 0 | + | NA | + | + | + | + | 0 | 0 |
| | 54 | F | 83 | Arthritis | 69 | RA | 14 | 0 | + | NA | + | + | + | + | 0 | 0 |
| Helfgott et al. [22] | 55 | M | 77 | L. pain | 39 | AE | 38 | + | + | NA | + | + | + | + | 0 | 0 |
| Sattar et al. [23] | 56 | M | 35 | L. pain | 25 | AE | 10 | 0 | + | NA | 0 | + | + | + | + | 0 |
| Martínez-Cordero et al. [24] | 57 | M | 38 | Arthritis | 28 | RA | 10 | NS | + | NA | + | + | + | + | 0 | 0 |
| Ferreiro Seoane et al. [25] | 58 | M | 44 | L. pain | 31 | AE | 13 | + | + | NA | + | + | + | NS | 0 | + |
| Toussirot and Acquaviva | 59 | M | 48 | Arthritis | 22 | RA | 26 | + | + | NA | 0 | 0 | + | 0 | 0 | 0 |
| | 60 | M | 77 | Arthritis | 35 | RA | 42 | 0 | + | NA | 0 | + | + | + | 0 | 0 |
| | 61 | F | 27 | Arthritis | 19 | RA | 8 | 0 | + | NA | + | + | + | + | 0 | 0 |
| Genc et al. [27] | 62 | F | 62 | Arthritis | 52 | RA | 10 | NS | 0 | NA | + | + | + | + | 0 | 0 |
| Guo et al. [28] | 63 | F | 30 | L. pain | 23 | AE | 7 | 0 | + | + | + | + | NS | + | 0 | 0 |
| Baksay et al. [29] | 64 | F | 57 | L. pain | 25 | AE | 32 | NS | + | + | + | + | + | + | 0 | 0 |
| Feijo et al. (2011) | 65 | F | 65 | L. pain | 64 | AE | 1 | 0 | + | + | + | + | + | + | 0 | 0 |
| Aghdashi et al. [31] | 66 | F | 70 | Arthritis | 58 | RA | 12 | NS | + | + | + | 0 | + | + | 0 | 0 |
| Dundar et al. [32] | 67 | M | 63 | L. pain | 51 | RA | 12 | NS | + | NS | + | + | NS | + | 0 | 0 |
| Koca et al. [38] | 68 | F | 38 | L. pain | 38 | RA | 1 | 0 | + | + | 0 | + | + | 0 | 0 | 0 |
| Barczyńska et al. [33] | 69 | F | 55 | Arthritis | 35 | RA | 20 | + | + | + | + | + | + | + | 0 | 0 |
| | 70 | M | 56 | L. pain | 34 | AE | 22 | NS | + | 0 | + | + | + | + | 0 | 0 |
| | 71 | M | 65 | NS | NS | NS | NS | + | 0 | + | + | + | + | + | 0 | 0 |
| Baccouche et al. [34] | 72 | F | 21 | L. pain | 20 | AE | 1 | 0 | + | + | + | + | + | + | 0 | 0 |
| Sargin and Gurer | 73 | F | 47 | L. pain | 45 | RA | 2 | 0 | NS | NS | NS | + | + | NS | 0 | 0 |
| Haridas and Kiran | 74 | F | 32 | Arthritis | 32 | AR | 1 | 0 | + | + | + | + | + | NS | 0 | 0 |
| Flores-Robles et al. (2020) | 75 | M | 55 | L. pain | 41 | AE | 14 | 0 | + | + | + | + | + | 0 | 0 | 0 |
| | 76 | F | 43 | Arthritis | 35 | RA | 8 | 0 | + | + | + | + | + | + | 0 | 0 |
| | 77 | F | 64 | Arthritis | 51 | RA | 13 | 0 | + | + | + | 0 | + | 0 | 0 | 0 |
| | 78 | M | 57 | Arthritis | 28 | RA | 29 | + | + | + | + | 0 | + | 0 | 0 | 0 |
| | 79 | M | 64 | L. pain | 49 | AE | 15 | 0 | + | + | + | + | + | 0 | 0 | 0 |
| | 80 | M | 63 | Arthritis | 47 | RA | 16 | 0 | + | + | + | + | + | 0 | 0 | 0 |
| | 81 | F | 75 | Arthritis | 70 | RA | 5 | 0 | + | + | + | + | + | + | 0 | 0 |

Ac. CCP: citrullinated peptide antibodies; AE: ankylosing spondylitis; Eros: radiographic erosions on hands and/or feet; extra-art involv: extra-articular involvement; F: female; L. pain: lumbar pain; M: male; NA: not applicable; NS: not specified by the author; RA: rheumatoid arthritis; RF: rheumatoid factor; SI: radiological sacroiliitis; Sind: spine syndesmophytes; sign +: existence/positive; sign 0: absence/negative.
Table 2: Clinical and epidemiological characteristics of 81 patients with concurrent RA and AE.

| Characteristic                              | n = 81   |
|--------------------------------------------|----------|
| Sex                                        |          |
| Male                                       | 58 (71.60%) |
| Mean age (years)*                          | 53.72 ± 14.83 |
| Onset mean age (years)*                    | 34.89 ± 14.47 |
| First disease diagnosed                    |          |
| Rheumatoid arthritis                       | 39/75 (52%) |
| Ankylosing spondylitis                     | 36/75 (40%) |
| Mean duration of disease (years)*          | 18.08 ± 13.16 |
| First symptom                              |          |
| Lumbar pain                                | 37/76 (48.68%) |
| Arthritis                                  | 35/76 (46.05%) |
| Uveitis                                    | 2/76 (2.81%) |
| Rheumatoid nodules                         | 38/73 (52.05%) |
| Inflammatory lumbar pain                   | 64/77 (83.12%) |
| Uveitis                                    | 11/81 (13.58%) |
| Extra-articular involvement (except uveitis)| 15/81 (18.51%) |
| Felty syndrome                             | 4/16     |
| Reactive arthritis                         | 3/16     |
| Sjögren’s syndrome                         | 2/16     |
| Vasculitis                                 | 2/16     |
| Membranous nephropathy                     | 2/16     |
| Dermatomyositis                            | 1/16     |
| Interstitial lung disease                  | 1/16     |

*Mean ± standard deviation.

Table 3: Radiological, laboratory, and treatment characteristics.

| Characteristic                              | n = 81 (percentage) |
|--------------------------------------------|---------------------|
| Syndesmophytes (radiograph/MR/CT)          | 42/57 (73.68%)      |
| Radiographic erosions                      | 65/76 (85.52%)      |
| Radiological sacroiliitis                  | 80/81 (98.76%)      |
| Positive RF                                | 73/79 (92.40%)      |
| Citrullinated peptide antibodies           | 16/18 (88.88%)      |
| Positive HLA B-27                          | 60/67 (89.55%)      |
| Treatment                                  |         |
| NSAIDs                                     | 28/47 (59.57%)      |
| Corticosteroids                            | 39/47 (82.97%)      |
| Gold salts                                  | 12/47 (25.53%)      |
| Hydroxychloroquine                         | 9/47 (19.14%)       |
| Sulfasalazine                              | 9/47 (19.14%)       |
| Methotrexate                               | 15/47 (31.91%)      |
| Leflunomide                                | 4/47 (8.51%)        |
| TNF-α-i                                    | 5/47 (10.63%)       |
| Others                                     | 6/47 (12.76%)       |

CT: computed tomography; MR: magnetic resonance, NSAIDs: non-steroidal anti-inflammatory drugs; RF: rheumatoid factor; TNF-α: tumor necrosis factor inhibitor.

Studies last data are in accordance with the fact that the manifestation of AS plays a determining role in axial affection when both entities coexist. 92% of the patients were RF+, and 90% were HLA B-27+. The previous statistic highlights the susceptibility of the patients’ joints and puts into question the extent to which inflammatory rheumatic diseases have well-defined pathophysiological borders.

With regard to treatment, a lot of discrepancies still exist due to the emergence of new therapies such as disease-modifying antirheumatic drugs (DMARDs) and biological agents. In this sense, it should be noted that 25% of the registered cases were treated with gold salts (a therapy currently in disuse in most countries). With the data presented, we do not know whether the association of both diseases conditions a resistance to the treatments currently available for both RA and AS.

With these data and as a summary, in young patients diagnosed with RA who present with extra-articular manifestations (such as uveitis) and clinical activity data in the axial skeleton, the coexistence of ankylosing spondylitis should be suspected and further studies should be carried out (mainly HLA B-27, X-rays of the dorsolumbar spine/sacroiliac joints, and, where appropriate, MRI scans). Similarly, in patients with AS who manifest symmetric arthritis, mainly in the upper limbs, and with erosive lesions found in radiological studies, the possibility of a concomitant diagnosis of RA should be considered.

Regarding this work’s weaknesses, the number of patients is limited, much of the published data is not very precise, and, in addition, the heterogeneity of the patients and the anachronism of the data make them difficult to analyze and, therefore, draw more precise conclusions.

Even so, to date, no other review exists that has been carried out in such an exhaustive manner. For this reason, we consider that its dissemination is important since it is likely that this association is being underestimated in clinical practice.
5. Conclusions

The association of RA and AS is highly infrequent; approximately 81 cases have been documented to date. The data presented in this review suggest that this association confers different characteristics since, in most cases, the patients have an erosive radiological pattern, RF and anti-CCP antibody positivity, and involvement of the axial skeleton and more frequently exhibit cutaneous nodules relative to patients with an isolated diagnosis of one of the two entities. More research is needed to support this conclusion.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] T. A. Simon, H. Kawabata, N. Ray, A. Baheti, S. Suissa, and J. M. Esdaile, “Prevalence of co-existing autoimmune disease in rheumatoid arthritis: a cross-sectional study,” *Advances in Therapy*, vol. 34, no. 11, pp. 2481–2490, 2017.

[2] D. Aletaha, T. Neogi, A. J. Silman et al., “Rheumatoid arthritis classification criteria: an american college of rheumatology/european league against rheumatism collaborative initiative,” *Arthritis & Rheumatism*, vol. 62, no. 9, pp. 2569–2581, 2010.

[3] W. P. Maksymowych and M. A. Brown, “Genetics of ankyllosing spondylitis and rheumatoid arthritis; where are we at currently, and how do they compare,” *Clinical & Experimental Rheumatology*, vol. 27, 2009.

[4] G. Can, D. Solmaz, O. Binici et al., “High frequency of inflammatory back pain and other features of spondyloarthritis in patients with rheumatoid arthritis,” *Rheumatology International*, vol. 33, no. 5, pp. 1289–1293, 2013.

[5] M. Dougados, S. V. D. Linden, R. Juhlin et al., “The European spondylarthropathy study group preliminary criteria for the classification of spondyloarthropathy,” *Arthritis & Rheumatism*, vol. 34, no. 10, pp. 1218–1227, 1991.

[6] W. Martel and I. F. Duff, “Pelvo-spondylitis in rheumatoid arthritis,” *Radiology*, vol. 77, no. 5, pp. 744–756, 1961.

[7] M. G. London and J. H. Bland, “Ankylosing spondylitis with subcutaneous nodules,” *Clinical Medicine*, vol. 71, pp. 533–534, 1964.

[8] S. H. Rosenthal, M. D. Lidsky, and J. T. Sharp, “Arthritis with nodules following ankyllosing spondylitis,” *JAMA*, vol. 206, no. 13, pp. 2893-2894, 1968.

[9] W. G. Van Valkenburgh, L. P. Georges, and R. Irby, “Aortic insufficiency and pelviospondylitis in a seropositive female with rheumatoid nodules,” *Arthritis & Rheumatism*, vol. 15, no. 5, pp. 544–552, 1972.

[10] H. S. Luthra, R. H. Ferguson, and D. L. Conn, “Coexistence of ankylosing spondylitis and rheumatoid arthritis,” *Arthritis & Rheumatism*, vol. 19, no. 1, pp. 111–114, 1976.

[11] J. R. Querol, J. T. Marse, A. D. Bru et al., “A new associated spondylarthiris: rheumatoid spondylarthiris,” *Revue du Rhumatisme et des Maladies Osteo-Articulaires*, vol. 43, pp. 411–418, 1976.

[12] A. E. Good, J. F. Hyla, and R. Rapp, “Ankylosing spondylitis with rheumatoid arthritis and subcutaneous nodules,” *Arthritis & Rheumatism*, vol. 20, no. 7, pp. 1434–1437, 1977.

[13] M. D. Clayman and J. L. Reinertsen, “Ankylosing spondylitis with subsequent development of rheumatoid arthritis, sjögren’s syndrome, and rheumatoid vasculitis,” *Arthritis & Rheumatism*, vol. 21, no. 3, pp. 383–389, 1978.

[14] L. R. Espinoza, F. B. Dove, and C. K. Osterland, “Coexistence of ankylosing spondylitis and rheumatoid arthritis in a single family,” *Arthritis & Rheumatism*, vol. 22, no. 2, pp. 203–204, 1979.

[15] P. Major, M. Dalinka, and P. Kline, “Coexisting rheumatoid arthritis and ankylosing spondylitis,” *American Journal of Roentgenology*, vol. 134, no. 5, pp. 1076–1079, 1980.

[16] J. P. Lemmer and W. R. Irby, “Coexistence of HLA-B-27 ankylosing spondylitis and DR4 seropositive nodular rheumatoid arthritis in patient with membranous nephropathy,” *Journal of Rheumatology*, vol. 8, no. 4, pp. 661–664, 1981.

[17] E. L. Alexander, W. B. Bias, and F. C. Arnett, “The coexistence of rheumatoid arthritis with Reiter’s syndrome and/or ankylosing spondylitis: a model of dual HLA-associated disease susceptibility and expression,” *Journal of Rheumatology*, vol. 8, no. 3, pp. 398–404, 1981.

[18] H. A. Lavery, T. Horner, and S. D. Roberts, “Rheumatoid arthritis, ankylosing spondylitis, and Reiter’s syndrome occurring simultaneously: case report,” *Sexually Transmitted Infections*, vol. 58, no. 3, pp. 196–199, 1982.

[19] D. Alarcon-Segovia and E. Martinez-Cordero, “Ankylosing spondylitis and rheumatoid arthritis in a patient with paget’s disease. differential effects of indomethacin, D-penicillamine, or gold sodium thiomolate in the respective arthritides,” *Archives of Internal Medicine*, vol. 145, no. 10, pp. 1915–1917, 1985.

[20] M. Serrano Comino, M. Garcia de la Torre, A. Roldán, F. Mampaso, and M. Serrano Rios, “Membranous nephropathy in a patient with ankylosing spondylitis and rheumatoid arthritis,” *Nephron*, vol. 40, no. 2, pp. 255–256, 1985.

[21] G. H. Fallet, C. G. Barnes, H. Berry, A. G. Mowat, H. Roux, and J. Villauymey, “Coexisting rheumatoid arthritis and ankylosing spondylitis,” *Journal of Rheumatology*, vol. 14, no. 6, pp. 1135–1138, 1987.

[22] S. M. Helfgott, G. Lazarides, and J. Sandberg-Cook, “Cooccurrence of rheumatoid arthritis and ankylosing spondylitis,” *Journal of Rheumatology*, vol. 15, no. 9, pp. 1451–1452, 1988.

[23] M. A. Sattar, A. A. Al-Sughyer, and R. Siboo, “Coexistence or rheumatoid arthritis, ankylosing spondylitis, and dermatomyositis in a patient with diabetes mellitus and the associated kinked HLA antigens,” *Rheumatology*, vol. 27, no. 2, pp. 146–149, 1988.

[24] E. Martínez-Cordero, J. López-Zepeda, and M. Del Carmen Fonseca, “Rheumatoid arthritis associated with ankylosing spondylitis defined by scintigraphic and CT abnormalities,” *Clinical Rheumatology*, vol. 11, no. 4, pp. 574–577, 1992.

[25] J. L. Ferreiro Seoane, N. Gomez Rodriguez, E. Formigo Rodriguez, A. Martinez Isla, and I. Anton Badiola, “The coexistence of rheumatoid arthritis, ankylosing spondylitis, and Reiter’s syndrome occurring simultaneously: case report,” *Annals of Rheumatic Diseases*, vol. 38, no. 7, pp. 452–454, 1993.

[26] T. H. Toussrot and P. C. Acquaviva, “Coexisting rheumatoid arthritis and ankylosing spondylitis, discussion of 3 cases with review of the literature,” *Clinical Rheumatology*, vol. 14, no. 5, pp. 554–560, 1995.

[27] H. Genc, B. Nacir, M. Saracoğlu, and H. R. Erdem, “Coexisting seronegative rheumatoid arthritis and ankylosing spondylitis,” *Clinical Rheumatology*, vol. 22, no. 6, pp. 503–504, 2003.

[28] Y. Y. Guo, L. L. Yang, H. D. Cui, S. Zhao, and N. Zhang, “Coexisting ankylosing spondylitis and rheumatoid arthritis:...
a case report with literature review,” *Chinese Medical Journal*, vol. 124, no. 20, pp. 3430–3432, 2011.

[29] B. Baksay, A. Dér, Z. Szekanecz, S. Szanto, and A. Kovacs, “Coexistence of ankylosing spondylitis and rheumatoid arthritis in a female patient,” *Clinical Rheumatology*, vol. 30, no. 8, pp. 1119–1122, 2011.

[30] V. Feijó Azevedo and P. Grachinski Buiar, “Concomitância de artrite reumatoide e espondilite anquilosante em um único paciente: importância dos novos critérios de clasificação,” *Revista Brasileira de Reumatologia*, vol. 53, no. 1, pp. 115–119, 2013.

[31] M. A. Agdashi, J. Zeinali, and Y. Roosta, “Rheumatoid arthritis and ankylosing occurring together,” *American-Eurasian Journal of Toxicological Sciences*, vol. 6, no. 4, pp. 83–86, 2014.

[32] U. Dundar, H. Cevik, U. S. Demirdal, and H. Tokas, “Use of rituximab to treat a patient with coexistence of rheumatoid arthritis and ankylosing spondylitis: 18 months follow-up,” *International Journal of Rheumatic Diseases*, vol. 21, 2014.

[33] T. A. Barczynska, M. Wegierska, P. Zuchowski et al., “Coexistence of rheumatoid arthritis and ankylosing spondylitis,” *Reumatologia/Rheumatology*, vol. 5, no. 5, pp. 279–285, 2015.

[34] K. Baccouche, M. Bouzaouche, and S. Belghali, “Diagnosis of association ankylosing spondylitis and rheumatoid arthritis: case report with literature review,” *Rheumatology: Current Research*, vol. 6, no. 4, pp. 1–3, 2016.

[35] G. H. Fallet, M. Mason, H. Berry, A. G. Mowat, I. Boussina, and J. Gerster, “Rheumatoid arthritis, and ankylosing spondylitis occurring together,” *BMJ*, vol. 1, no. 6013, pp. 804–807, 1976.

[36] M. Wilkinson and E. G. L. Bywaters, “Clinical features and course of ankylosing spondylitis as seen in a follow-up of 222 hospital referred cases,” *Annals of the Rheumatic Diseases*, vol. 17, no. 2, pp. 209–228, 1958.

[37] E. C. Huskisson, F. D. Hart, and D. L. Conn, “Ankylosing spondylitis and rheumatoid arthritis,” *Proceedings of the Royal Society of Medicine*, vol. 63, no. 6, pp. 620–621, 1970.

[38] I. Koca, A. Tetoglu, M. Ucar, O. Altindag, and E. Madenci, “Bilateral sacroilitis in patients with early rheumatoid arthritis,” *Turkish Journal of Physical Medicine and Rehabilitation*, vol. 60, no. 1, pp. 72–75, 2014.

[39] B. Sargin and G. Gurer, “Rituximab induce remission in a patient with rheumatoid arthritis and ankylosing spondylitis,” *International Journal of Clinical Rheumatology*, vol. 12, no. 4, pp. 101–104, 2017.

[40] V. M. Haridas and H. Kiran, “A rare co-occurrence of anti CCP-positive rheumatoid arthritis with sacroilitis,” *IJRCI*, vol. 7, no. 1, 2019.